Sangamo Therapeutics, Inc. Presents Pipeline And Technology Advances At The American Society Of Gene & Cell Therapy Annual Meeting

Published: 2026-04-30 11:36:50 ET SGMO

Published on 04/30/2026 at 11:36 am EDT

Sangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo?s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology. Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo?s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets ?

specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo?s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.

Neurology Epigenetic Regulation: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy. Abstract No. 1309.

Poster Presentation ? Tuesday, May 12, 5:00-6:30pm EDT. Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain.

Abstract No. 1469. Poster Presentation ?

Tuesday, May 12, 5:00-6:30pm EDT. Next-Generation Genome Engineering: Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus. Abstract No.

105. Oral Presentation ? Tuesday, May 12, 4:00-4:15pm EDT.

Session Name: Next-generation platforms for precise therapeutic genome editing and integration.